Last reviewed · How we verify
CKD-333 formulation II — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CKD-333 formulation II (CKD-333 formulation II) — Chong Kun Dang Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CKD-333 formulation II TARGET | CKD-333 formulation II | Chong Kun Dang Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CKD-333 formulation II CI watch — RSS
- CKD-333 formulation II CI watch — Atom
- CKD-333 formulation II CI watch — JSON
- CKD-333 formulation II alone — RSS
Cite this brief
Drug Landscape (2026). CKD-333 formulation II — Competitive Intelligence Brief. https://druglandscape.com/ci/ckd-333-formulation-ii. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab